Skip To Main Content
Gianantonio Rosti on Muck Rack

Gianantonio Rosti

As seen in: Nature, Medscape
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gianantonio

Contact Gianantonio, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial

|
By Hagop Kantarjian, Michael Deininger, Jane F. Apperley, Charles Chuah, Andreas Hochhaus Verified, Hugues de Lavallade, Jeffrey Lipton, Elza Lomaia, James McCloskey, Lori J. Maness, Michael S Mauro, Beatriz Moiraghi, Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, Alexander Vorog, Niti Patel, Meliessa Hennessy, Tammie C. Yeh, Jorge Cortés, Christopher Kevin Arthur, L. Evan Reddick
| Nature Verified
Abstract The primary analysis of the phase 2 OPTIC trial (NCT02467270) demonstrated optimal benefit:risk with response-based ponatinib dosing (45 mg once daily (QD) reduced to 15 mg QD) upon achieving ≤1% BCR::ABL1IS in patients with tyrosine kinase inhibitor-resistant or T315I-positive chronic-phase chronic myeloid leukemia (CP-CML). Here, we report 5-year long-term outcomes.
Open in Who Shared Issue with article?

Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study | Leukemia

|
By Gianantonio Rosti, Tim H. Brümmendorf, Fausto Castagnetti, Carlo Gambacorti-Passerini, Thomas Ernst, Luke Kuttschreuter
| Nature Verified
Abstract In the phase 4 BYOND trial, patients with pretreated chronic myeloid leukemia (CML) received bosutinib (starting dose: 500 mg/day). Efficacy and safety after ≥3 years of follow-up in 156 patients with Philadelphia chromosome–positive chronic phase CML by age and Charlson Comorbidity Index scores (without the age component; mCCI) is reported.
Open in Who Shared Issue with article?

Clinical Challenges in Chronic Phase CML

|
By Gianantonio Rosti, Tim Hughes MD, Andreas Hochhaus Verified
| Medscape Verified
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel Spectacular advances in the management of chronic myeloid leukaemia means that many patients diagnosed today have near normal life expectancy. Nevertheless, some journeys are not as smooth, and complacency in the chronic phase of CML can have a devastating impact on patient outcomes.
Open in Who Shared Issue with article?
See all 5 articles